DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0052718A1 Rangel (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0052718A1 Rangel (43) Pub US 2011 0052718A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0052718A1 Rangel (43) Pub. Date: Mar. 3, 2011 (54) SYNERGISTIC PHYTOCEUTICAL A6IR 36/4I (2006.01) COMPOSITIONS A636/7 (2006.01) A636/74 (2006.01) (76) Inventor: José Angel Olalde Rangel, Caracas A636/734 (2006.01) (VE) A6IR 36/45 (2006.01) A6II 35/32 (2006.01) (21) Appl. No.: 12/942,766 A6IP 9/00 (2006.01) A6IP5/00 (2006.01) (22) Filed: Nov. 9, 2010 A6IP 700 (2006.01) Related U.S. Application Data (52) U.S. Cl. .................................... 424/549; 424/195.15 (60) Division of application No. 1 1/271,940, filed on Nov. (57) ABSTRACT 10, 2005, now Pat. No. 7,303,772, Continuation of Phytoceutical compositions for the prevention and treatment application No. 12/705,525, filed on Feb. 12, 2010. of circulatory disorders, feminine endocrine disorders, and O O dermal disorders. A specific combination of extracts of plants Publication Classification is taught, as well as principles for varying the formulations (51) Int. Cl. based on categorizing plants into one of three groups, Energy, A6 IK 36/074 (2006.01) Bio-Intelligence, and Organization and selecting several A6 IK 36/258 (2006.01) plants from each group. Such combinations have synergistic A6 IK 36/28 (2006.01) effects, with minimal side effects. riographic eficience afiabetic rati remissists, irreiraig fest of treatast aetgees hairs. appier trasound se Patent Application Publication Mar. 3, 2011 Sheet 1 of 3 US 2011/0052718A1 fisiae : yesigraisie eitiece 3 filiateig cit reasissists, it airig eigth of treatifier eater ghatas. Doppler Ultrascard e Patent Application Publication Mar. 3, 2011 Sheet 2 of 3 US 2011/0052718A1 Figure 2: Ficts before after echosartographic carnparisor. Enterval between echesonagraris is a trants sia's ser Patent Application Publication Mar. 3, 2011 Sheet 3 of 3 US 2011/0052718A1 Figure 3: Photographic eviderace of severe Psoriasis rentissions, including ength of treatenter between photos US 2011/0052718A1 Mar. 3, 2011 SYNERGISTC PHYTOCEUTICAL 0009. Another embodiment of the invention provides a COMPOSITIONS composition for chronic skin disorders. It can be used alone or combined with pharmaceuticals, and can be used to treat PRIOR RELATED APPLICATIONS diseases such as psoriasis, dermatitis, skin infections, shingles (herpes Zoster), boils, eczema, rash, acne or burn, 0001. Not applicable. and the like. FEDERALLY SPONSORED RESEARCH STATEMENT DETAILED DESCRIPTION OF THE FIGURES 0002. Not applicable. 0010 FIG. 1 shows representative examples of diabetic foot lesions treated with the herbaria of Table 1. REFERENCE TO MICROFICHEAPPENDIX (0011 FIG. 2 shows representative examples of PCOS treated with the herbaria of Table 2. 0003) Not applicable. 0012 FIG. 3 shows representative examples of psoriasis FIELD OF THE INVENTION treated with the herbaria of Table 3. 0004. The invention relates to phytoceutical formulations DETAILED DESCRIPTION OF THE INVENTION used to treat a variety of diseases. The formulations are par ticular combinations of plants and have synergistic effect in 0013 “Pharmaceutically acceptable excipients' is used combination. Principles for selecting beneficial formulations hereinaccording to art accepted meanings, and includes those are provided. ingredients needed to formulate a medicine for mammalian use, including the use of gelatin capsules. BACKGROUND OF THE INVENTION 0014 “Synergistic' or “synergy” is used herein to mean that the effect is more than its additive property. In preferred 0005. The academic study of medicinal plants for the treatment of diverse diseases has been nearly as pervasive as embodiments, the synergy is at least 1.5, 2, 5, or 10 fold. the study of Western medicines The active principles from 0015. By use of “plants.” what is meant herein is that the many traditional medicines have been extracted from plants, plant (or that portion with medicinal activity) is used whole, the curative agents identified and their mechanisms of action ground, or as an extract. Also included are purified active determined. Plant based medicines are typically well toler ingredients and derivatives thereof. However, it is believed ated, with less severe side effects as well as a smaller range of that the best efficacy of plants used herein is achieved with the side effects. However, despite the excellent medicinal quali use of the entire plant or its extracts, rather than with the use ties of many plants, they are individually insufficient to take of isolated active ingredients. chronic degenerative diseases into remission. In contrast, 0016 Further, although plants are named here according while synthetic drugs can be highly effective, their use is to commonly used nomenclature, with improving taxonomy often hampered by severe side effects. What is needed in the plants are often reclassified. Whenever a plant is referenced, art are better treatment regimes with improved patient toler it includes related species with similar active ingredients. ance, while providing sufficient efficacy. 0017. The following examples are illustrative only and should not serve to unduly limit the invention. SUMMARY OF THE INVENTION 0006. A number of known beneficial plants were classified Example 1 according to their capacity to enhance the three main ele ments that support overall health: Energy (E), Bio-intelli Plant Characteristics Circulatory Disorders gence (I) and Organization (O). A synergistic effect is 0018 Angelica sinensis (Dong Quai or Angelica, also expected when all three categories of herbs (E. I. O) are Angelica Archangelia, Angelica Pubescens and Angelica included in a formulation, preferably at least two or three or Sylvestris) contains terpenes (terpenes, mainly B-phelland four plants from each category. Thus, one embodiment of the rene, with B-bisabolene, B-caryophyllene, B-phellandrene, C.- invention provides a method of selecting additional disease and B-pinene, limonene, linalool, borneol, acetaldehyde, treating formulations according to these principles. Three examples of formulations prepared in this way are provided menthadienes, and nitromenthadienes), macrocyclic lactones and additional formulations are being prepared and tested. (including tridecanolide, 12-methyl tridecanolide, pentade 0007 Another embodiment of the invention provides an canolide), phthalates (such as hexamethylphthalate), cou effective, natural composition for treating circulatory dis marins (especially furocoumarin glycosides such as eases. The composition can be used alone, or can be com marmesin and apterin), angelicin and byakangelicin deriva bined with simultaneous use of one or more pharmaceutical tives (osthol, umbelliferone, psoralen, bergapten, impera compositions. It can be used for the treatment of diabetic toren, XanthotoXol, Xanthotoxin, oxypeucedanin and more), lesions, obliterative arteriosclerosis, Leriche Syndrome as well as various Sugars, plant acids, flavonoids, and sterols. (aorto-iliac obliteration), Buerger's disease (thromboangiitis 0019 Acanthopanax senticosus (Russian Ginseng, Sibe obliterans), thrombophlebitis, chronic venous insufficiency, rian Ginseng, Eleuthero, Devil's Shrub, Touch-me-not, Wild Varicose veins, varicose ulcers, hemorrhoids, and the like. Pepper, Shigoka, Acantopanacis senticosus) contains terpe 0008 Another embodiment of the invention provides a noids (oleanolic acid), glycosides (Eleutheroside A (daucos composition for the treatment offeminine endocrine diseases terin), B1, C-G, I, K, L, M), phytosterols (B-sitosterol), cou that can be used alone or combined with pharmaceuticals. It marins (Eleutheroside B1 and B3, isofraxidine), provides an effective medicine for diseases such as Polycystic polysaccharides (eleutherans), Volatile oils, caffeic acid, Ovary Syndrome, ovarian cysts, fibrocystic breast condition, coniferyl aldehyde, and Sugars. Eleuthero has been shown to uterine fibroids, dysfunctional uterine hemorrhage, female bind to estrogen, progestin, and mineralocorticoid receptors, infertility, premenstrual syndrome, amenorrhea, and the like. and stimulate T-lymphocyte and natural killer cell produc US 2011/0052718A1 Mar. 3, 2011 tion. It has activity anti-plateletaggregation activity similar to pfaffic acids, phytosterols (sitosterol and estimasterol). It also aspirin, as well as antioxidant activity. Russian Ginsengcon contains Saponins. Its germanium content probably accounts tains at least 40 active ingredients. for its properties as an oxygenator at the cellular level, and its 0020 Rhaponticum carthamoides (Leuzea, or Maral high iron content may account for its traditional use for ane Root) contains a mixture of compounds called, “levseins.” mia. This herb increases oxygenation at the cellular level, and LeVSeins represents a complex of more than 10 ecdysterones it also has anabolic activity at the muscular and cardiac levels including 20-beta-ecdysterone, makisterone C, 24-dehydro by improving the contraction of the miocardia and diminish makisterone A, carthamosterone, polypodyne B and ajugas ing arrhythmias and stabilizing the membranes of cardiac terone C. Researchers extracted and purified various ecdys cells. The incorporation of this phytomedicine provides 44 teroids from Rhaponticum and found that the ecdysteroids active principles in a single therapeutic. increased the mass of the developing quails in a dose-depen 0024 Rhodiola rosea (Golden Root, Roseroot) consists dent manner, with the rate of increase proportional to the mainly of phenylpropanoids (rosavin, rosin, rosarin (specific
Load more

Recommended publications
  • Suspect and Target Screening of Natural Toxins in the Ter River Catchment Area in NE Spain and Prioritisation by Their Toxicity
    toxins Article Suspect and Target Screening of Natural Toxins in the Ter River Catchment Area in NE Spain and Prioritisation by Their Toxicity Massimo Picardo 1 , Oscar Núñez 2,3 and Marinella Farré 1,* 1 Department of Environmental Chemistry, IDAEA-CSIC, 08034 Barcelona, Spain; [email protected] 2 Department of Chemical Engineering and Analytical Chemistry, University of Barcelona, 08034 Barcelona, Spain; [email protected] 3 Serra Húnter Professor, Generalitat de Catalunya, 08034 Barcelona, Spain * Correspondence: [email protected] Received: 5 October 2020; Accepted: 26 November 2020; Published: 28 November 2020 Abstract: This study presents the application of a suspect screening approach to screen a wide range of natural toxins, including mycotoxins, bacterial toxins, and plant toxins, in surface waters. The method is based on a generic solid-phase extraction procedure, using three sorbent phases in two cartridges that are connected in series, hence covering a wide range of polarities, followed by liquid chromatography coupled to high-resolution mass spectrometry. The acquisition was performed in the full-scan and data-dependent modes while working under positive and negative ionisation conditions. This method was applied in order to assess the natural toxins in the Ter River water reservoirs, which are used to produce drinking water for Barcelona city (Spain). The study was carried out during a period of seven months, covering the expected prior, during, and post-peak blooming periods of the natural toxins. Fifty-three (53) compounds were tentatively identified, and nine of these were confirmed and quantified. Phytotoxins were identified as the most frequent group of natural toxins in the water, particularly the alkaloids group.
    [Show full text]
  • PHD PHARMACOGNOSY- EMMANUEL K. KUMATIA.Pdf
    ANALGESIC AND ANTI-INFLAMMATORY CONSTITUENTS OF ANNICKIA POLYCARPA STEM AND ROOT BARKS AND CLAUSENA ANISATA ROOT A THESIS SUBMITTED IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN THE DEPARTMENT OF PHARMACOGNOSY FACULTY OF PHARMACY AND PHARMACEUTICAL SCIENCES COLLEGE OF HEALTH SCIENCES BY EMMANUEL KOFI KUMATIA KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (KNUST) KUMASI-GHANA AUGUST, 2016 DECLARATION I declare that this thesis is the product of my own research work. It does not contain any manuscript that was earlier accepted for the award of any other degree in any University nor any published work of anybody except where cited and due acknowledgments made in the text. ……………………………….. ……………………… Emmanuel Kofi Kumatia Date ………………………………… ……………………… Prof. (Mrs.) Rita Akosua Dickson Date (Supervisor) ……………………………...... ……………………… Prof. Kofi Annan Date (Supervisor) ……………………………...... ……………………… Prof. Abraham Yeboah Mensah Date (Head of Department of Pharmacognosy) ii DEDICATIONS This work is especially dedicated to my mother, Madam Veronica Akoto, my wife, Mrs. Anne Boakyewaa Anokye-Kumatia and my children, Evzen Fifii Kumatia and Eliora Nana Akua Kumatia. iii ABSTRACT Clausena anisata and Annickia polycarpa are medicinal plants used to treat various painful and inflammatory disorders among other ailments in traditional medicine. The aim of this study was to investigate the analgesic/antinociceptive and anti-inflammatory activities of the ethanol extracts of C. anisata root (CRE), A. polycarpa stem (ASE) and root barks (AR) in order to provide scientific justification for their use as anti-inflammatory and analgesic agents. Analgesic activity was evaluated using the hot plate and the acetic acid induced writhing assays. The mechanism of antinociception was evaluated by employing pharmacological antagonism assays at the opioid and cholinergic receptors in the hot plate and the writhing assays.
    [Show full text]
  • Chemical Profiles and Simultaneous Quantification of Aurantii Fructus By
    molecules Article Chemical Profiles and Simultaneous Quantification of Aurantii fructus by Use of HPLC-Q-TOF-MS Combined with GC-MS and HPLC Methods Yingjie He 1,2,† ID , Zongkai Li 3,†, Wei Wang 2, Suren R. Sooranna 4 ID , Yiting Shi 2, Yun Chen 2, Changqiao Wu 2, Jianguo Zeng 1,2, Qi Tang 1,2,* and Hongqi Xie 1,2,* 1 Hunan Key Laboratory of Traditional Chinese Veterinary Medicine, Hunan Agricultural University, Changsha 410128, China; [email protected] (Y.H.); [email protected] (J.Z.) 2 National and Local Union Engineering Research Center for the Veterinary Herbal Medicine Resources and Initiative, Hunan Agricultural University, Changsha 410128, China; [email protected] (W.W.); [email protected] (Y.S.); [email protected] (Y.C.); [email protected] (C.W.) 3 School of Medicine, Guangxi University of Science and Technology, Liuzhou 565006, China; [email protected] 4 Department of Surgery and Cancer, Chelsea and Westminster Hospital, Imperial College London, London SW10 9NH, UK; [email protected] * Correspondence: [email protected] (Q.T.); [email protected] (H.X.); Fax: +86-0731-8461-5293 (H.X.) † These authors contributed equally to this work. Received: 1 August 2018; Accepted: 29 August 2018; Published: 30 August 2018 Abstract: Aurantii fructus (AF) is a traditional Chinese medicine that has been used to improve gastrointestinal motility disorders for over a thousand years, but there is no exhaustive identification of the basic chemical components and comprehensive quality control of this herb. In this study, high-performance liquid chromatography coupled with quadrupole time of flight mass spectrometry (HPLC-Q-TOF-MS) and gas chromatography coupled mass spectrometry (GC-MS) were employed to identify the basic chemical compounds, and high-performance liquid chromatography (HPLC) was developed to determine the major biochemical markers from AF extract.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases Chemicals Found in Ammi Majus
    Dr. Duke's Phytochemical and Ethnobotanical Databases Chemicals found in Ammi majus Activities Count Chemical Plant Part Low PPM High PPM StdDev Refernce Citation 0 5-HYDROXYMARMESIN Plant -- 10 5-METHOXY-PSORALEN Plant -- 0 5-[2-(3- Plant 1000.0 -- METHYLBUTYROXY)-3- HYDROXY-3- METHYLBUTOXY]-PS. 1 5-[2-(ACETOXY)-3- Seed 1000.0 -- HYDROXY-3- METHYLBUTOXY]- PSORALEN 21 8-METHOXY-PSORALEN Plant -- 0 8-[2-(3- Plant 100.0 -- METHYLBUTYROXY)-3- HYDROXY-3- METHYLBUTOXY]-PS. 4 ALLOIMPERATORIN Seed 1.0 -- 0 AMMAJIN Seed -- 0 AMMIDIN Plant -- 0 AMMIFURIN Seed -- 0 AMMIRIN Seed -- 1 AMMOIDIN Plant -- 0 ANGALCIN Plant -- 17 ANGELICIN Plant -- 0 ANGENOMALIN Plant -- 26 BERGAPTEN Seed 400.0 3100.0 0.22232578675103337 -- 4 CALCIUM-OXALATE Seed -- 0 CAMESOL Plant -- 0 CAMPESELOL Plant -- 0 CAMPESENIN Plant -- 0 CAMPESIN Plant -- 1 CELLULOSE Seed 224000.0 1.1650981847855737 -- 0 COUMARINIC-ACID Plant -- 0 DELTOIN Plant -- Activities Count Chemical Plant Part Low PPM High PPM StdDev Refernce Citation 0 DIHYDROOROSELSELONE Plant -- 0 DL-PIPERITONE Seed 1000.0 -- 0 EO(ASS.) Seed 10000.0 -- 0 FAT Seed 129400.0 -0.71629528571714 -- 0 FURANOCHROMONE Plant -- 0 FURANOCOUMARIN Plant -- 9 FUROCOUMARIN Plant -- 0 GLYCOSIDES Seed 10000.0 -1.1706691766863613 -- 2 HERACLENIN Seed 700.0 -- 25 IMPERATORIN Seed 100.0 8000.0 1.111306994003492 -- 8 ISOIMPERATORIN Seed -- 15 ISOPIMPINELLIN Seed -- 3 ISOQUERCETIN Seed -- 11 ISORHAMNETIN Plant -- 1 ISORHAMNETIN-3- Leaf -- GLUCOSIDE 0 ISORHAMNETIN-3- Leaf -- GLUCURONIDE 2 ISORHAMNETIN-3- Leaf -- RUTINOSIDE 0 KAEMPFEROL-7-O-
    [Show full text]
  • Taste Modulator and Method of Use Thereof Geschmacksmodulator Und Verfahren Zur Verwendung Davon Modulateur De Goût Et Son Procédé D’Utilisation
    (19) TZZ¥ZZ_T (11) EP 3 005 884 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A23L 27/10 (2016.01) A23L 7/126 (2016.01) 19.04.2017 Bulletin 2017/16 A21D 2/26 (2006.01) A21D 2/36 (2006.01) A23L 2/56 (2006.01) A61Q 11/00 (2006.01) (2017.01) (2006.01) (21) Application number: 15189164.5 A61K 8/97 A61K 36/232 A23L 23/00 (2016.01) (22) Date of filing: 09.10.2015 (54) TASTE MODULATOR AND METHOD OF USE THEREOF GESCHMACKSMODULATOR UND VERFAHREN ZUR VERWENDUNG DAVON MODULATEUR DE GOÛT ET SON PROCÉDÉ D’UTILISATION (84) Designated Contracting States: • JOHN, Thumpalasseril V. AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Morganville, NJ 07751 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • KIM, Jung-A PL PT RO RS SE SI SK SM TR Edgewater, NJ 07020 (US) • SINGH, Ajay Pratap (30) Priority: 10.10.2014 US 201414511963 Highland Park, NJ 08904 (US) (43) Date of publication of application: (74) Representative: Lawrence, John 13.04.2016 Bulletin 2016/15 Barker Brettell LLP 100 Hagley Road (73) Proprietor: International Flavors & Fragrances Inc. Edgbaston New York, NY 10019 (US) Birmingham B16 8QQ (GB) (72) Inventors: (56) References cited: • CHIN, Hsi-Wen EP-A1- 2 641 479 WO-A1-2013/085014 Tinton Falls, NJ 07724 (US) JP-A- 2006 191 826 JP-A- 2007 176 919 JP-B1- 4 606 505 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Jj--T) Plant Tissue [3] and Correlations of Virulence with Ability Me to Produce Toxin in Vitro [4]
    Phytochemistry. Vol. 27. No.3. pp. 767 771. 1988. {)()J I 9422/RR UOO +0.00 Printed in Greal Britain. Pergamon Journals LId. , INHIBITION OF TRICHOTHECENE TOXIN BIOSYNTHESIS BY NATURALLY OCCURRING SHIKIMATE AROMATICS A. E. DESJARDINS, R. D. PLAITNER and G. F. SPENCER Northern Regional Research Center. Agricultural Research Service. U.S. Department of Agriculture. 1815 North University Street. Peoria, Ulinois 61604, U.S.A. (Revised received 18 August 1987) Key Word Index-Umbelliferae; Leguminosae; furanocoumarins; flavonoids; Fusaria; trichothecene toxins. Abstract-Certain naturally occurring flavonoids and furanocoumarins are inhibitors of trichothecene toxin biosynthesis. These compounds block T-2 biosynthesis in liquid cultures of Fusarium sporotrichioides NRRL 3299 at concentrations substantially less than required to block fungal growth. Inhibited cultures accumulate variable amounts of trichodiene. the hydrocarbon precursor of the trichothecenes. These inhibitors appear to block the trichothecene biosynthetic pathway after formation of trichodiene and before formation of highly oxygenated trichothecenes. Exposure to these widely occurring plant shikimate aromatics may inhibit trichothecene production during plant pathogenesis. INTRODUCTION Plants produce a great diversity ofsecondary metabolites as normal constituents and as phytoalexins induced by fungal infection. Many of these compounds have been shown to inhibit fungal growth in vitro and have been postulated to similarly restrict fungal growth in plant tissues [1]. Although most research on phytoalexiris and related compounds has concerned their direct fungi­ toxicity. some plant metabolites have also shown indirect ,.. 2 toxin R '" OCOCH1CH (Meh effects such as inactivation of fungal hydrolytic enzymes Neosolaniol R '" OH [2]. Diacetoxyscirpenol R '" H Plant pathogenic species of Fusarium produce a wide variety of phytotoxic secondary metabolites including trichothecene toxins.
    [Show full text]
  • 1 Alkaloid Drugs
    1 Alkaloid Drugs Most plant alkaloids are derivatives of tertiary amines, while others contain primary, secondary or quarternary nitrogen. The basicity of individual alkaloids varies consider- ably, depending on which of the four types is represented. The pK, values (dissociation constants) lie in the range of 10-12 for very weak bases (e.g. purines), of 7-10 for weak bases (e.g. Cinchona alkaloids) and of 3-7 for medium-strength bases (e.g. Opium alkaloids). 1.1 Preparation of Extracts Alkaloid drugs with medium to high alkaloid contents (31%) Powdered drug (Lg) is mixed thoroughly with Iml 10Yo ammonia solution or 10% General method, Na,CO, solution and then extracted for lOmin with 5ml methanol under reflux. The extraction filtrate is then concentrated according to the total alltaloids of the specific drug, so that method A 100p1 contains 50-100pg total alkaloids (see drug list, section 1.4). Rarmalae semen: Powdered drug (Ig) is extracted with lOml methanol for 30min Exception under reflux. The filtrate is diluted 1:10 with methanol and 20pl is used for TLC. Strychni semen: Powdered seeds (Ig) are defatted with 20 rnl n-hexane for 30min under reflux. The defatted seeds are then extracted with lOml methanol for lOmin under reflux. A total of 30yl of the filtrate is used for TL.C. Colchici semen: Powdered seeds (1 g) are defatted with 20 ml n-hexane for 30 min under reflux. The defiitted seeds are then extracted for 15 min with 10ml chloroform. After this, 0.4ml 10% NH, is added to the mixture, shaken vigorously and allowed to stand for about 30min before fillration.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/008994.6 A1 Olalde Rangel (43) Pub
    US 2008.00899.46A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/008994.6 A1 Olalde Rangel (43) Pub. Date: Apr. 17, 2008 (54) SYNERGISTIC PHYTOCEUTICAL A6IR 36/21 (2006.01) COMPOSITIONS A6IR 36/232 (2006.01) A6IR 36/258 (2006.01) (76) Inventor: Jose Angel Olalde Rangel, Caracas A6IR 36/28 (2006.01) (VE) A6IR 36/286 (2006.01) A6IR 36/3 (2006.01) Correspondence Address: A6IR 36/4I (2006.01) BAKER & MCKENZE LLP A6IR 36/45 (2006.01) Pennzoil Place, South Tower A6IR 36/48 (2006.01) 711 Louisiana, Suite 3400 A6IR 36/7 (2006.01) HOUSTON, TX 77002-2716 (US) A6IP 7/00 (2006.01) A6IP 5/00 (2006.01) (21) Appl. No.: 11/924,122 A6IP 9/00 (2006.01) (52) U.S. Cl. .................... 424/548; 424/195.15; 424/725: (22) Filed: Oct. 25, 2007 424/726; 424/728; 424/732: 424/737; 424/752; 424/755; Related U.S. Application Data 424/757; 424/773; 424/775 (62) Division of application No. 1 1/271,940, filed on Nov. (57) ABSTRACT 10, 2005, now Pat. No. 7,303,772. Phytoceutical compositions for the prevention and treatment Publication Classification of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of (51) Int. Cl. plants is taught, as well as principles for varying the for A6 IK 36/00 (2006.01) mulations based on categorizing plants into one of three A6 IK 35/32 (2006.01) groups, Energy, Bio-Intelligence, and Organization and A6 IK 36/074 (2006.01) selecting several plants from each group.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tuberculosis
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tuberculosis Chemical Activity Count (+)-3-HYDROXY-9-METHOXYPTEROCARPAN 1 (+)-8HYDROXYCALAMENENE 1 (+)-ALLOMATRINE 1 (+)-ALPHA-VINIFERIN 3 (+)-AROMOLINE 1 (+)-CASSYTHICINE 1 (+)-CATECHIN 10 (+)-CATECHIN-7-O-GALLATE 1 (+)-CATECHOL 1 (+)-CEPHARANTHINE 1 (+)-CYANIDANOL-3 1 (+)-EPIPINORESINOL 1 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-GALBACIN 2 (+)-GALLOCATECHIN 3 (+)-HERNANDEZINE 1 (+)-ISOCORYDINE 2 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 2 (+)-T-CADINOL 1 (+)-VESTITONE 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-3-HYDROXY-9-METHOXYPTEROCARPAN 1 (-)-ACANTHOCARPAN 1 (-)-ALPHA-BISABOLOL 2 (-)-ALPHA-HYDRASTINE 1 Chemical Activity Count (-)-APIOCARPIN 1 (-)-ARGEMONINE 1 (-)-BETONICINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 2 (-)-BORNYL-FERULATE 2 (-)-BORNYL-P-COUMARATE 2 (-)-CANESCACARPIN 1 (-)-CENTROLOBINE 1 (-)-CLANDESTACARPIN 1 (-)-CRISTACARPIN 1 (-)-DEMETHYLMEDICARPIN 1 (-)-DICENTRINE 1 (-)-DOLICHIN-A 1 (-)-DOLICHIN-B 1 (-)-EPIAFZELECHIN 2 (-)-EPICATECHIN 6 (-)-EPICATECHIN-3-O-GALLATE 2 (-)-EPICATECHIN-GALLATE 1 (-)-EPIGALLOCATECHIN 4 (-)-EPIGALLOCATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN-GALLATE 9 (-)-EUDESMIN 1 (-)-GLYCEOCARPIN 1 (-)-GLYCEOFURAN 1 (-)-GLYCEOLLIN-I 1 (-)-GLYCEOLLIN-II 1 2 Chemical Activity Count (-)-GLYCEOLLIN-III 1 (-)-GLYCEOLLIN-IV 1 (-)-GLYCINOL 1 (-)-HYDROXYJASMONIC-ACID 1 (-)-ISOSATIVAN 1 (-)-JASMONIC-ACID 1 (-)-KAUR-16-EN-19-OIC-ACID 1 (-)-MEDICARPIN 1 (-)-VESTITOL 1 (-)-VESTITONE 1
    [Show full text]
  • Division of Pharmaceutical Biology Faculty of Pharmacy University of Helsinki
    Division of Pharmaceutical Biology Faculty of Pharmacy University of Helsinki Plant secondary metabolites in Peucedanum palustre and Angelica archangelica and their plant cell cultures Manu Juho Mikael Eeva ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Pharmacy of the University of Helsinki, for public criticism in Auditorium LS.2 (A109) (Latokartanonkaari 7 – Building B) on May 21th, 2010, at 12 o´clock noon. HELSINKI 2010 Supervisors Prof. Heikki Vuorela Ph. D. (Pharm.) Division of Pharmaceutical Biology Faculty of Pharmacy, University of Helsinki, Finland Prof. Pia Vuorela Ph. D. (Pharm.) Pharmaceutical Sciences Åbo Akademi University, Turku, Finland Prof. Raimo Hiltunen Ph. D. (Pharm.) Division of Pharmaceutical Biology Faculty of Pharmacy, University of Helsinki, Finland Reviewers Prof. Riitta Julkunen-Tiitto Ph. D. Department of Biology University of Eastern Finland, Finland Prof. Juha-Pekka Salminen Ph. D. Department of Chemistry University of Turku, Finland Opponent Prof. Elín Soffía Ólafsdóttir Ph. D. (Pharm.) Faculty of Pharmacetical Sciences School of Health Sciences University of Iceland, Iceland ISBN: 978-952-10-6186-8 (paperback) ISSN 1795-7079 ISBN 978-952-10-6187-5 (PDF) http://ethesis.helsinki.fi/ Yliopistopaino, Helsinki 2010 CONTENTS 1 ACKNOWLEDGEMENTS 5 2 ABSTRACT 7 3 LIST OF ORIGINAL PUBLICATIONS 8 4 ABBREVIATIONS 9 5 INTRODUCTION 10 6 REVIEW OF THE LITERATURE 12 6.1 Botany and distribution of A. archangelica and P. palustre 12 6.2 Ethnobotany of A. archangelica and P. palustre 14 6.3
    [Show full text]
  • Supplementary Materials
    Supplementary materials: Figure S1 T-test plot of the significant difference in variables Table S1 Detail information of commercial oil samples Table S2 Retention time, scan parameters and calibration curve of target compounds Table S3 Observation of metabolites in isoflavonoids biosynthesis pathway Figure S1 T-test plot of the significant difference in variables Table S1 Detail information of commercial oil samples Sample No. Vendor Origin of raw materials Supermarket Specifications CSO1 Lin Long Wuhan, Hubei Carrefour, Wuhan 5L CSO2 Jin Longyu Wuhan, Hubei Supermarket, Wuhan 1.8L CSO3 Fu Linmen Suzhou, Jiangsu RT-MART, Wuhan 1.8L CSO4 Fu Linmen Tianjin Jingkelong Supermarket, Beijing 900mL CSO5 Zhong An Heilongjiang WU MART, Beijing 5L CSO6 Hong Qingting Chongqing Yonghui Superstore, Chongqing 5L CSO7 Ying Mai Zhongshan, Guangdong Supermarket, Chongqing 5L CSO8 Yuan Bao Guangzhou, Guangdong Carrefour, Guangzhou 5L CSO9 Jin Ye Zhenjiang, Jiangsu Supermarket, Hangzhou 1.8L CRO1 Dao Daoquan Nanjing, Jiangsu RT-MART, Wuhan 1.8L CRO2 Ao Xing Xiangyang, Hubei RT-MART, Wuhan 1.8L CRO3 Hengda Xing’an Huhehot, Inner Mongolia Jingkelong Supermarket, Beijing 500mL CRO4 Xian Can Chengdu, Sichuan Supermarket, Chongqing 900mL CRO5 Hong Qingting Chongqing Yonghui Superstores, Chongqing 1L CRO6 Wu Hu Huanggang, Hubei Supermarket, Chongqing 5L CRO7 Dao Mai Shenzhen, Guangdong Supermarket, Guangzhou 2L CRO8 Lao Xiang Shenzhen, Guangdong Carrefour, Guangzhou 900mL CRO9 Fu Linmen Maoming, Guangdong Supermarket, Chongqing 900mL CRO10 Fu Linmen Suzhou, Jiangsu Supermarket, Hangzhou 1.5L CRO11 Chu Laixiang Hangzhou, Zhejiang Supermarket, Hangzhou 1.8L CSO, Commercial soybean oil CRO, Commercial rapeseed oil Table S2 Retention time, scan parameters and calibration curve of target compounds Scan RT Precursor Daughter CE1 Daughter CE2 Tube Calibration curve R2 LOQ Liner range No.
    [Show full text]
  • Chemistry and Health Effects of Furanocoumarins in Grapefruit
    journal of food and drug analysis xxx (2016) 1e13 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.jfda-online.com Review Article Chemistry and health effects of furanocoumarins in grapefruit * Wei-Lun Hung, Joon Hyuk Suh, Yu Wang Citrus Research and Education Center, Department of Food Science and Human Nutrition, University of Florida, Lake Alfred, FL, USA article info abstract Article history: Furanocoumarins are a specific group of secondary metabolites that commonly present in Received 1 September 2016 higher plants, such as citrus plants. The major furanocoumarins found in grapefruits 0 0 Received in revised form (Citrus paradisi) include bergamottin, epoxybergamottin, and 6 ,7 -dihydroxybergamottin. 2 November 2016 During biosynthesis of these furanocoumarins, coumarins undergo biochemical modifi- Accepted 3 November 2016 cations corresponding to a prenylation reaction catalyzed by the cytochrome P450 enzymes Available online xxx with the subsequent formation of furan rings. Because of undesirable interactions with several medications, many studies have developed methods for grapefruit furanocoumarin Keywords: quantification that include high-performance liquid chromatography coupled with UV anticancer activity detector or mass spectrometry. The distribution of furanocoumarins in grapefruits is bergamottin affected by several environmental conditions, such as processing techniques, storage bone health temperature, and packing materials. In the past few years, grapefruit furanocoumarins furanocoumarins have been demonstrated to exhibit several biological activities including antioxidative, grapefruit -inflammatory, and -cancer activities as well as bone health promotion both in vitro and in vivo. Notably, furanocoumarins potently exerted antiproliferative activities against cancer cell growth through modulation of several molecular pathways, such as regulation of the signal transducer and activator of transcription 3, nuclear factor-kB, phosphatidy- linositol-3-kinase/AKT, and mitogen-activated protein kinase expression.
    [Show full text]